Susquehanna Advisors Group Inc. Purchases Shares of 184,200 Adaptive Biotechnologies Corporation $ADPT

Susquehanna Advisors Group Inc. purchased a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 2nd quarter, HoldingsChannel reports. The fund purchased 184,200 shares of the company’s stock, valued at approximately $3,951,000.

A number of other hedge funds also recently made changes to their positions in the stock. AQR Capital Management LLC lifted its stake in shares of Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Adaptive Biotechnologies by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP bought a new position in Adaptive Biotechnologies during the 1st quarter worth approximately $93,000. New York State Common Retirement Fund raised its holdings in Adaptive Biotechnologies by 39.2% during the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after purchasing an additional 13,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock worth $4,417,000 after purchasing an additional 333,379 shares during the period. 99.17% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Adaptive Biotechnologies news, Director Peter M. Neupert sold 124,690 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $25.15, for a total value of $3,135,953.50. Following the transaction, the director owned 130,625 shares in the company, valued at approximately $3,285,218.75. This represents a 48.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Hershberg sold 30,664 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.40, for a total value of $748,201.60. Following the completion of the sale, the director directly owned 46,683 shares of the company’s stock, valued at $1,139,065.20. This trade represents a 39.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,062,325 shares of company stock worth $46,659,069 over the last 90 days. 5.70% of the stock is owned by company insiders.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $25.19 on Monday. The firm has a market cap of $4.02 billion, a PE ratio of -61.44 and a beta of 2.08. Adaptive Biotechnologies Corporation has a 52-week low of $12.00 and a 52-week high of $26.87. The business’s 50 day moving average price is $22.92 and its two-hundred day moving average price is $17.66. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business earned ($0.17) EPS. On average, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ADPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. TD Cowen lifted their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley boosted their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, BTIG Research increased their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average price target of $24.42.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.